Converting enzyme inhibitor temocaprilat prevents high glucose-mediated suppression of human aortic endothelial cell proliferation.
D000470:Alkaloids; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000008:administration & dosage / Q000493:pharmacokinetics*; D001011:Aorta / Q000166:cytology* / Q000187:drug effects* / Q000378:metabolism; D053119:Benzophenanthridines; D001920:Bradykinin / Q000031:analogs & derivatives* / Q000037:antagonists & inhibitors; D065094:Bradykinin B2 Receptor Antagonists; D002455:Cell Division / Q000187:drug effects* / Q000502:physiology; D002462:Cell Membrane / Q000201:enzymology; D002478:Cells, Cultured; D003331:Coronary Vessels / Q000166:cytology; D004305:Dose-Response Relationship, Drug; D042783:Endothelial Cells / Q000187:drug effects* / Q000201:enzymology / Q000378:metabolism; D005947:Glucose / Q000008:administration & dosage / Q000009:adverse effects / Q000037:antagonists & inhibitors*; D006801:Humans; D009281:Naphthalenes / Q000008:administration & dosage / Q000493:pharmacokinetics; D018384:Oxidative Stress / Q000187:drug effects / Q000502:physiology; D010617:Phenanthridines / Q000008:administration & dosage / Q000493:pharmacokinetics; D011493:Protein Kinase C / Q000037:antagonists & inhibitors / Q000187:drug effects / Q000378:metabolism; D043783:Receptor, Bradykinin B1 / Q000008:administration & dosage / Q000502:physiology; D043782:Receptor, Bradykinin B2 / Q000502:physiology; D013841:Thiazepines / Q000494:pharmacology*; D013997:Time Factors
D000470:Alkaloids; D000806:Angiotensin-Converting Enzyme Inhibitors; D053119:Benzophenanthridines; D065094:Bradykinin B2 Receptor Antagonists; D009281:Naphthalenes; D010617:Phenanthridines; D043783:Receptor, Bradykinin B1; D043782:Receptor, Bradykinin B2; D013841:Thiazepines; C069156:temocaprilat; C051090:bradykinin, Leu(8)-des-Arg(9)-; C065679:icatibant; C016299:chelerythrine; D011493:Protein Kinase C; C058819:calphostin C; D005947:Glucose; D001920:Bradykinin